The EACR’s fifth edition of Goodbye Flat Biology will focus on the next generation of cancer models and emerging topics in the areas of cell architecture, mechanobiology, the immune microenvironment, intravital imaging, and high-content analysis for cancer therapeutics. It will seek to emphasize complex 3D model systems that capture the dialogue between cancer cells, the cellular stroma (e.g. fibroblasts, immune cells), and the extracellular matrix, with a focus on how this dialogue affects cancer progression and treatment response. Keynote lectures will be provided by Erik Sahai from the Crick Institute, Matthias Lütolf from EPFL, and Anne Rios from the Princess Máxima Center for Pediatric Oncology.
Who should attend?
Faculty, postdocs, and graduate students interested in the techniques and applications of next generation cancer models at the intersection of cancer biology, engineering, and drug development; industry scientists interested in identifying innovative platforms for drug discovery and targets for novel therapies; and journal editors interested in cutting-edge cancer biology and drug discovery research.
Speakers: Emmanuel Donnadieu (Institut Cochin, France), Andrew Ewald (Johns Hopkins University, USA), Peter Friedl (Radboud UMC, Netherlands), Jacky Goetz (INSERM, France), Bram Heijs (Leiden University, Netherlands), Henriëtte Lanz (MIMETAS, Netherlands), Matthias Lütolf (EPFL, Switzerland), Laura Machesky (University of Cambridge, UK), Leo Price (Crown Bioscience, Netherlands), Anne Rios (Princess Máxima Center, The Netherlands), Erik Sahai (Crick Institute, UK), Silvia Scaglione (React4Life, Italy), Daniela Thommen (NKI, The Netherlands), Paul Timpson (Garvan Institute, Australia), Britta Trappmann (Max Planck Institute, Germany), and Valerie Weaver (UCSF, USA)
Keywords: next generation cancer models, cell architecture, mechanobiology, immune microenvironment, intravital imaging, high-content analysis, cancer therapeutics, organoids, bioengineered systems, in vivo models, tumor tissue environment, 3D model systems, cellular stroma, fibroblasts, immune cells, extracellular matrix, molecular regulation, cancer cell adhesion, cancer cell invasion, cancer cell migration, force generation, mechanotransduction, 3D in vitro systems, target identification, compound screening, anti-tumor immunity, oncology
Who should attend?
Faculty, postdocs, and graduate students interested in the techniques and applications of next generation cancer models at the intersection of cancer biology, engineering, and drug development; industry scientists interested in identifying innovative platforms for drug discovery and targets for novel therapies; and journal editors interested in cutting-edge cancer biology and drug discovery research.
Speakers: Emmanuel Donnadieu (Institut Cochin, France), Andrew Ewald (Johns Hopkins University, USA), Peter Friedl (Radboud UMC, Netherlands), Jacky Goetz (INSERM, France), Bram Heijs (Leiden University, Netherlands), Henriëtte Lanz (MIMETAS, Netherlands), Matthias Lütolf (EPFL, Switzerland), Laura Machesky (University of Cambridge, UK), Leo Price (Crown Bioscience, Netherlands), Anne Rios (Princess Máxima Center, The Netherlands), Erik Sahai (Crick Institute, UK), Silvia Scaglione (React4Life, Italy), Daniela Thommen (NKI, The Netherlands), Paul Timpson (Garvan Institute, Australia), Britta Trappmann (Max Planck Institute, Germany), and Valerie Weaver (UCSF, USA)
Keywords: next generation cancer models, cell architecture, mechanobiology, immune microenvironment, intravital imaging, high-content analysis, cancer therapeutics, organoids, bioengineered systems, in vivo models, tumor tissue environment, 3D model systems, cellular stroma, fibroblasts, immune cells, extracellular matrix, molecular regulation, cancer cell adhesion, cancer cell invasion, cancer cell migration, force generation, mechanotransduction, 3D in vitro systems, target identification, compound screening, anti-tumor immunity, oncology
